Assuntos
Deficiência de GATA2/genética , Fator de Transcrição GATA2/genética , Linfo-Histiocitose Hemofagocítica/genética , Paniculite/genética , Adolescente , Doenças Assintomáticas , Pai , Feminino , Deficiência de GATA2/fisiopatologia , Humanos , Infecções/fisiopatologia , Linfedema/fisiopatologia , Linfo-Histiocitose Hemofagocítica/fisiopatologia , Mosaicismo , Mutação , Pancitopenia/fisiopatologia , Paniculite/fisiopatologia , Linhagem , Recidiva , Choque/fisiopatologia , IrmãosRESUMO
Some patients with pancytopenia do not conform to any diagnostic criteria of known haematological or non-haematological diseases; however, they respond well to corticosteroid, high-dose intravenous immunoglobulin and rituximab treatment. This abnormality is termed immunorelated pancytopenia (IRP). Later studies indicated that IRP might be a kind of autoimmune disease in which T helper (Th) type 2 cell function is enhanced, resulting in the hyperfunction of B lymphocytes, which then produce excess autoantibodies that attack the bone marrow (BM) and cause cytopenia. Hypofunction of regulatory T (Treg) cells and enhanced Th17 cell function, an elevated percentage of plasmacytoid dendritic cells (pDCs) and a decreased percentage of natural killer (NK) cells help to promote the process. Moreover, increased expression of a synergistic stimulator of B lymphocytes, CD70 and the reactive overexpression of the BCR inhibitory coreceptor CD22 also support this claim. Candidate autoantigens targeted by autoantibodies on haematopoietic cell membranes have also been reported in IRP. This review is focused on studies that demonstrate the role of immune responses in the pathogenesis of IRP. Current diagnostic criteria and treatments for IRP are also referenced to provide a thorough understanding. Distinguishing IRP from idiopathic cytopenias of undetermined significance (ICUS) and other haematological disorders, for example myelodysplastic syndrome (MDS), aplastic anaemia (AA), paroxysmal nocturnal hemoglobinuria (PNH) and Evans syndrome, may help patients with pancytopenia benefit from proper treatment. Further studies are required to achieve new insight into the pathophysiology of IRP with regard to the immune system, which will be instrumental for the development of novel therapies for inhibiting disease initiation and/or progression.
Assuntos
Pancitopenia/imunologia , Pancitopenia/fisiopatologia , Humanos , Pancitopenia/diagnósticoRESUMO
Idiopathic portal hypertension (IPH) and extrahepatic portal venous obstruction (EHPVO) are prototype noncirrhotic causes of portal hypertension (PHT), characterized by normal hepatic venous pressure gradient, variceal bleeds, and moderate to massive splenomegaly with preserved liver synthetic functions. Infections, toxins, and immunologic, prothrombotic and genetic disorders are possible causes in IPH, whereas prothrombotic and local factors around the portal vein lead to EHPVO. Growth failure, portal biliopathy, and minimal hepatic encephalopathy are long-term concerns in EHPVO. Surgical shunts and transjugular intrahepatic portosystemic shunt resolve the complications secondary to PHT. Meso-Rex shunt is now the standard-of-care surgery in children with EHPVO.
Assuntos
Hipertensão Portal/fisiopatologia , Cirrose Hepática/fisiopatologia , Pancitopenia/fisiopatologia , Veia Porta , Esplenomegalia/fisiopatologia , Trombose Venosa/fisiopatologia , Animais , Doenças Biliares/etiologia , Doenças Biliares/terapia , Gerenciamento Clínico , Modelos Animais de Doenças , Progressão da Doença , Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/prevenção & controle , Hemorragia Gastrointestinal/terapia , Transtornos do Crescimento/etiologia , Encefalopatia Hepática/etiologia , Encefalopatia Hepática/terapia , Humanos , Hipertensão Portal/complicações , Hipertensão Portal/diagnóstico , Hipertensão Portal/etiologia , Hipertensão Portal/metabolismo , Hipertensão Portal/terapia , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/metabolismo , Transplante de Fígado , Metabolômica , Pancitopenia/complicações , Pancitopenia/diagnóstico , Pancitopenia/metabolismo , Derivação Portossistêmica Cirúrgica , Derivação Portossistêmica Transjugular Intra-Hepática , Qualidade de Vida , Esplenomegalia/complicações , Esplenomegalia/diagnóstico , Esplenomegalia/metabolismo , Transcriptoma , Trombose Venosa/complicações , Trombose Venosa/diagnóstico , Trombose Venosa/metabolismo , Hipertensão Portal não Cirrótica IdiopáticaRESUMO
BACKGROUND AND AIM: Idiopathic portal hypertension (IPH) refers to a relatively rare condition characterized by intrahepatic portal hypertension in the absence of underlying disease such as liver cirrhosis. METHODS: We retrospectively reviewed 338 patients with IPH that were diagnosed at the pathological consultation center of our hospital. RESULTS: The ratio of male to female patients was 1:1. Mean age at onset was 35.1 ± 16.5 years; male patients on average were 12 years younger than female patients at onset. The median duration from onset to IPH diagnosis was 12 months. In 50 patients, medication use may have been an etiological factor. The most common clinical manifestations were splenomegaly (91.3%) and hypersplenism (68.9%); 57.0% patients presented varicosis, while 25.1% patients had a history of variceal bleeding. Nodular regenerative hyperplasia was found in 22.2% liver biopsies. Among patients for whom laboratory data were available, 65.0%, 50.3%, and 71.4% patients presented leukopenia, anemia, and thrombocytopenia due to hypersplenism. Liver function was mostly in the compensated stage. Female patients showed worse leukopenia and anemia, while male patients were more likely to have abnormal serum transaminase and bilirubin levels. Sixty-seven patients received surgical or interventional treatment. CONCLUSIONS: High-quality liver biopsy, detailed clinical information, and expert pathologist are necessary for diagnosis of IPH. IPH can occur concurrently with other liver disease such as hepatitis and drug-induced liver injury. Medication appears to be an important etiological factor for IPH in China. Management approach was largely focused on treatment of portal hypertension and its complications.
Assuntos
Hipertensão Portal/patologia , Cirrose Hepática/patologia , Fígado/patologia , Pancitopenia/patologia , Esplenomegalia/patologia , Adolescente , Adulto , Biópsia , China/epidemiologia , Feminino , Humanos , Hipertensão Portal/epidemiologia , Hipertensão Portal/fisiopatologia , Hipertensão Portal/terapia , Cirrose Hepática/epidemiologia , Cirrose Hepática/fisiopatologia , Cirrose Hepática/terapia , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Pancitopenia/epidemiologia , Pancitopenia/fisiopatologia , Pancitopenia/terapia , Pressão na Veia Porta , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Esplenomegalia/epidemiologia , Esplenomegalia/fisiopatologia , Esplenomegalia/terapia , Adulto Jovem , Hipertensão Portal não Cirrótica IdiopáticaRESUMO
Primary hyperoxaluria is a rare disease whose incidence is estimated at less than 1 cases/million inhabitants/year. This is a congenital abnormality of hepatic metabolism leading to an endogenous overproduction of oxalate with excess urinary excretion. We report the case of a 43-year-old patient, was followed to end-stage renal disease hemodialysis, consulting for anemic syndrome with mucocutaneous pallor. Laboratory tests found pancytopenia with aplastic anemia. Bone marrow was difficult to achieve, bringing medullary blood hyperdilué and uninterpretable . Radiographs showed a homogeneous splenomegaly and small dedifferentiated a kidney marrow biopsy was performed. Histological examination revealed a myelofibrosis and birefringent crystals in polarized light, diagnosis retained: spinal oxalosis.
Assuntos
Anemia Aplástica/diagnóstico , Hiperoxalúria Primária/diagnóstico , Pancitopenia/diagnóstico , Adulto , Biópsia , Feminino , Humanos , Hiperoxalúria Primária/fisiopatologia , Falência Renal Crônica/terapia , Pancitopenia/fisiopatologia , Diálise Renal/métodos , Esplenomegalia/diagnóstico por imagemRESUMO
PURPOSE: A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described. SUMMARY: A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue. The patient had a history of recurrent CDI, recurrent urinary tract infections, nephrolithiasis, chronic hepatitis C, and endometriosis. Her previous therapies for CDI included metronidazole, vancomycin, rifaximin, and fecal microbiota transplantation. On admission, she had a platelet count of 172,000 platelets/mm3, hemoglobin concentration of 11.1 g/dL, and white blood cell (WBC) count of 3,100 cells/mm3. Within 24 hours of the first dose of fidaxomicin and before the second dose, the patient's platelet count fell to 156,000 platelets/mm3, her hemoglobin concentration decreased to 9.9 g/dL, and her WBC count fell to 2,600 cells/mm3. Values for all 3 tests continued to decrease during the first few days of fidaxomicin therapy. One dose of filgrastim 300 µg was administered subcutaneously on day 6 in response to the pancytopenia, after which the platelet, hemoglobin, and WBC values stabilized for a day and then generally declined. Platelet, hemoglobin, and WBC values returned to normal within 3 days of the patient's last dose of fidaxomicin. Use of the Naranjo et al. adverse drug reaction probability scale indicated a probable association (score of 6) between fidaxomicin and the patient's pancytopenia. CONCLUSION: A 33-year-old woman developed pancytopenia during a course of fidaxomicin therapy for CDI. Platelet, hemoglobin, and WBC values returned to normal within 3 days of the final fidaxomicin dose.
Assuntos
Antibacterianos/efeitos adversos , Fidaxomicina/efeitos adversos , Pancitopenia/induzido quimicamente , Adulto , Antibacterianos/administração & dosagem , Infecções por Clostridium/tratamento farmacológico , Feminino , Fidaxomicina/administração & dosagem , Humanos , Injeções Subcutâneas , Pancitopenia/fisiopatologiaRESUMO
BACKGROUND: Idiopathic portal hypertension (IPH) and extrahepatic portal venous obstruction (EHPVO) are non-cirrhotic vascular causes of portal hypertension (PHT). Variceal bleed and splenomegaly are the commonest presentations. AIM: The present review is intended to provide the existing literature on etiopathogenesis, clinical profile, diagnosis, natural history and management of IPH and EHPVO. RESULTS: IPH and EHPVO are both characterized by normal hepatic venous pressure gradient, moderate to massive splenomegaly with preserved liver synthetic functions. While the level of block in IPH is presinusoidal, in EHPVO it is at prehepatic level. Infections, autoimmunity, drugs, immunodeficiency and prothrombotic states are possible etiological agents in IPH. Contrastingly in EHPVO, prothrombotic disorders and local factors around the portal vein are the incriminating factors. Diagnosis is often clinical, supported by simple radiological tools. Natural history is defined by episodes of variceal bleed and symptoms related to enlarged spleen. Growth failure, portal biliopathy and minimal hepatic encephalopathy are additional concerns in EHPVO. Long-term survival is reasonably good with endoscopic surveillance; however, parenchymal extinction leading to decompensation is seen in a minority of patients in both the disorders. Surgical shunts revert the complications secondary to PHT. Meso-Rex shunt has become the standard surgery in children with EHPVO. CONCLUSION: This review gives a detailed summary of these two vascular conditions of liver-IPH and EHPVO. Further research is needed to understand the pathogenesis and natural history of these disorders.
Assuntos
Varizes Esofágicas e Gástricas/complicações , Hemorragia Gastrointestinal/etiologia , Hipertensão Portal/diagnóstico , Hipertensão Portal/fisiopatologia , Veias Jugulares/transplante , Cirrose Hepática/diagnóstico , Cirrose Hepática/fisiopatologia , Fígado/irrigação sanguínea , Pancitopenia/diagnóstico , Pancitopenia/fisiopatologia , Veia Porta/fisiopatologia , Esplenomegalia/diagnóstico por imagem , Enxerto Vascular/métodos , Trombose Venosa/cirurgia , Animais , Varizes Esofágicas e Gástricas/fisiopatologia , Hemorragia Gastrointestinal/patologia , Hemorragia Gastrointestinal/prevenção & controle , Hemorragia Gastrointestinal/terapia , Hemostase Endoscópica/métodos , Humanos , Hipertensão Portal/patologia , Hipertensão Portal/terapia , Fígado/patologia , Fígado/fisiopatologia , Cirrose Hepática/etiologia , Cirrose Hepática/patologia , Cirrose Hepática/terapia , Modelos Animais , Pancitopenia/patologia , Pancitopenia/terapia , Pressão na Veia Porta/fisiologia , Veia Porta/patologia , Veia Porta/cirurgia , Esplenomegalia/diagnóstico , Esplenomegalia/etiologia , Esplenomegalia/patologia , Esplenomegalia/fisiopatologia , Esplenomegalia/terapia , Ultrassonografia Doppler/métodos , Trombose Venosa/complicações , Hipertensão Portal não Cirrótica IdiopáticaRESUMO
INTRODUCTION: Pancytopenia is a relatively common hematological entity and is a manifestation of many illnesses which can be life threatening at times. The severity of pancytopenia and the underlying pathology determine the management and prognosis. This study was conducted to evaluate hematological and bone marrow findings in patients presenting with pancytopenia. METHODS: A prospective observational study was conducted in Department of Pathology, Manipal College of Medical Sciences, Pokhara from January 2011 to December 2016. Clinical and hematological parameters including bone marrow aspiration and biopsy were evaluated in all patients who presented with pancytopenia. RESULTS: Among 138 cases studied, patients' age ranged from 2 to 82 years with a mean age of 43.95 years, and there was male predominance. Most of the patients presented with generalized weakness, pallor, dypnoea and fever. Hypoplastic marrow was seen in 38 (27.5%) cases, followed by 26 (18.8%) cases of megaloblastic anemia and 19 (13.76%) cases of acute leukemia. Other findings included one case each of hemophagocyosis, leishmaniasis, plasmodium vivex malaria and metastatic carcinoma. CONCLUSIONS: This study highlights that pancytopenia is a common hematological problem and that the study of detailed primary hematological investigations along with bone marrow study in patients with pancytopenia will help to identify the cause for further planning and management.
Assuntos
Anemia Megaloblástica/fisiopatologia , Medula Óssea/patologia , Leucemia/fisiopatologia , Pancitopenia/fisiopatologia , Doença Aguda , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anemia Megaloblástica/sangue , Anemia Megaloblástica/complicações , Anemia Megaloblástica/patologia , Anorexia/etiologia , Anorexia/fisiopatologia , Criança , Pré-Escolar , Dispneia/etiologia , Dispneia/fisiopatologia , Febre/etiologia , Febre/fisiopatologia , Hemorragia/etiologia , Hemorragia/fisiopatologia , Hepatomegalia/etiologia , Hepatomegalia/fisiopatologia , Humanos , Leucemia/sangue , Leucemia/complicações , Leucemia/patologia , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Debilidade Muscular/fisiopatologia , Nepal , Palidez/etiologia , Palidez/fisiopatologia , Pancitopenia/sangue , Pancitopenia/complicações , Pancitopenia/patologia , Estudos Prospectivos , Esplenomegalia/etiologia , Esplenomegalia/fisiopatologia , Centros de Atenção Terciária , Adulto JovemRESUMO
Non-cirrhotic portal hypertension was first described by Guido BANTI in 1898 as a condition characterized by the association of portal hypertension with splenomegaly, anemia and healthy liver. The diagnosis was based on abdominal ultrasound, splenoportography and liver biopsy. Our study aimed to evaluate the role of splenectomy in non-cirrhotic portal hypertension. We conducted a retrospective study of 3 patients (2 women and 1 man) treated by our staff over the period January 2010 -September 2016. The diagnosis of idiopathic portal hypertension was based on the following criteria: portal hypertension, the presence of oesophageal varices associated with splenomegaly, the absence of cirrhosis or of other liver disorders responsible of portal hypertension. All patients underwent splenectomy. Outcome after splenectomy was marked by the standardization of clinical, radiological and biological signs of this disease associated with the absence of oesophageal varices recurrence. Splenectomy associated with ligation of oesophageal varices may be sufficient to treat this syndrome and especially its consequences without using splenorenal bypass.
Assuntos
Varizes Esofágicas e Gástricas/etiologia , Hipertensão Portal/cirurgia , Cirrose Hepática/cirurgia , Pancitopenia/cirurgia , Esplenectomia/métodos , Esplenomegalia/cirurgia , Adulto , Feminino , Humanos , Hipertensão Portal/diagnóstico , Hipertensão Portal/fisiopatologia , Cirrose Hepática/diagnóstico , Cirrose Hepática/fisiopatologia , Masculino , Pancitopenia/diagnóstico , Pancitopenia/fisiopatologia , Estudos Retrospectivos , Esplenomegalia/diagnóstico , Esplenomegalia/fisiopatologia , Resultado do Tratamento , Adulto Jovem , Hipertensão Portal não Cirrótica IdiopáticaRESUMO
BACKGROUND: For the final step of the maturation of the ribosome, the nascent 40S and 60S subunits are exported from the nucleus to the cell cytoplasm. To prevent premature association of these ribosomal subunits, eukaryotic initiation factor 6 (eIF6) binds the 60S subunit within the nucleus. Its release in the cytoplasm requires the interaction of EFL1 and SDBS proteins. In Shwachman-Diamond syndrome (SDS), a defective SDBS protein prevents eIF6 eviction, inhibiting its recycle to the nucleus and subsequent formation of the active 80S ribosome. OBJECTIVE: This study aims to identify the molecular basis of an SDS-like disease, manifested by pancytopenia, exocrine pancreatic insufficiency and skeletal abnormalities in six patients from three unrelated families. METHODS: Whole exome analysis was used for mutation identification. Fluorescence microscopy studies assessed the localisation of Tif6-GFP, the yeast eIF6 homologue, in yeast WT and mutant cells. Human and yeast EFL1 proteins, WT and mutants, were expressed in Saccharomyces cerevisiae BCY123 strain, and circular dichroism and small-angle X-ray scattering were used to assess the folding and flexibility of these proteins. Green malachite colorimetric assay was performed to determine the GTPase activity of WT and Efl1 mutants. RESULTS: Four patients were homozygous for p.R1095Q variant and two patients were homozygous for p.M882K variant in EFL1. Residue R1095 and M882 are conserved across species. Neither the GTPase activity of the mutant proteins nor its activation by the SDBD protein or the 60S ribosomal subunit were affected. Complementation of efl1Δ yeast cells with the EFL1 mutants rescued the slow growth phenotype. Nonetheless, Tif6-GFP was relocalised to the cytoplasm in mutant yeast cells in contrast to its nuclear localisation in WT cells. CONCLUSIONS: Mutations in EFL1 clinically manifest as SDS-like phenotype. Similar to the molecular pathology of SDS, mutant EFL1 proteins do not promote the release of cytoplasmic Tif6 from the 60S subunit, likely preventing the formation of mature ribosomes.
Assuntos
Doenças da Medula Óssea/genética , Osso e Ossos/anormalidades , Insuficiência Pancreática Exócrina/genética , GTP Fosfo-Hidrolases/genética , Lipomatose/genética , Mutação , Pancitopenia/genética , Doenças da Medula Óssea/complicações , Doenças da Medula Óssea/enzimologia , Doenças da Medula Óssea/fisiopatologia , Criança , Pré-Escolar , Insuficiência Pancreática Exócrina/complicações , Insuficiência Pancreática Exócrina/enzimologia , Insuficiência Pancreática Exócrina/fisiopatologia , Feminino , GTP Fosfo-Hidrolases/química , GTP Fosfo-Hidrolases/metabolismo , Variação Genética , Humanos , Lactente , Lipomatose/complicações , Lipomatose/enzimologia , Lipomatose/fisiopatologia , Masculino , Pancitopenia/complicações , Pancitopenia/fisiopatologia , Fatores de Alongamento de Peptídeos , Dobramento de Proteína , Ribonucleoproteína Nuclear Pequena U5 , Subunidades Ribossômicas Maiores de Eucariotos/metabolismo , Saccharomyces cerevisiae/genética , Síndrome de Shwachman-Diamond , Sequenciamento do ExomaRESUMO
Leukemia cutis develops in <4% of all acute leukemias. Concurrent acute myeloid leukemia (AML) and Langerhans cell histiocytosis (LCH) is rare, with most cases involving lymph nodes or spleen, and no cutaneous involvement. We report the case of a 59-year-old man who presented with fever, malaise, and fatigue. The CBC showed leukocytosis (30.4 × 10/L, 9% blasts), anemia, and thrombocytopenia. Bone marrow biopsy was diagnosed with AML, not otherwise specified, with mutations of FLT3 and IDH2 (R140Q). The patient developed skin rash on the right flank with the clinical differential diagnosis of herpes simplex virus or varicella-zoster virus infection/reactivation versus leukemia cutis. A skin biopsy showed leukemia cutis in mid and deep dermis. Immunohistochemistry positive for CD4, CD33, CD117, and myeloperoxidase (MPO) supported myeloid and monocytic differentiation. Clusters of Langerhans cells positive for S100, CD1a, CD4, langerin and aberrant CD33 and MPO were found admixed with the AML cells. Langerhans cells were negative for BRAF V600E by immunohistochemistry. The diagnosis of leukemia cutis and concomitant LCH was established. The aberrant expression of CD33 and MPO shared by AML and LCH suggests a possible relationship among these 2 lesions. No LCH or Langerhans cell differentiation was found in the bone marrow. The patient achieved complete remission 4 months after chemotherapy and the skin lesions resolved. To our knowledge, we present for the first time a case of concomitant cutaneous LCH and leukemia cutis.
Assuntos
Histiocitose de Células de Langerhans/complicações , Histiocitose de Células de Langerhans/patologia , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/patologia , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Biópsia por Agulha , Transplante de Medula Óssea/métodos , Progressão da Doença , Evolução Fatal , Histiocitose de Células de Langerhans/tratamento farmacológico , Humanos , Imuno-Histoquímica , Leucemia Mieloide Aguda/terapia , Masculino , Pessoa de Meia-Idade , Pancitopenia/induzido quimicamente , Pancitopenia/fisiopatologia , Neoplasias Cutâneas/tratamento farmacológico , Listas de EsperaRESUMO
No disponible
Assuntos
Humanos , Feminino , Adulto , Pancitopenia/complicações , Pancitopenia/dietoterapia , Pancitopenia/diagnóstico , Deficiência de Vitamina B 12/complicações , Deficiência de Vitamina B 12/dietoterapia , Vitamina B 12/uso terapêutico , Pancitopenia/tratamento farmacológico , Pancitopenia/fisiopatologia , Estomatite Aftosa/complicações , Radiografia Torácica/métodos , Gastrite Atrófica/complicaçõesRESUMO
Multiparameter flow cytometric analysis allows for precise evaluation of growth factor stimulated intracellular signaling in distinct immunophenotype defined hematopoetic populations. Our analysis of intracellular phosphoprotein in response to major hematopoietic growth factors or cytokines showed several interesting findings. Although there was no characteristic signaling abnormality that was diagnostic for MDS, MDS cases were often associated with more signaling aberrancies involving more cellular populations. Higher than average response in the CD34(+)CD117(+) progenitor cells to Flt3 ligand and stem cell factor stimulation was frequently associated with high risk features or disease progression in MDS. Although preliminary results hint an adverse prognostic role of dysregulated FLT3 pathway in MDS cases, whether this observation adds independent prognostic value to the existing prognostic system needs to be further explored in future prospective studies.
Assuntos
Citometria de Fluxo/métodos , Hematopoese/genética , Fatores de Crescimento de Células Hematopoéticas/farmacologia , Imunofenotipagem/métodos , Síndromes Mielodisplásicas/fisiopatologia , Pancitopenia/fisiopatologia , Fosfoproteínas/análise , Transdução de Sinais , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/patologia , Células Cultivadas , Citocinas/farmacologia , Humanos , Sistema de Sinalização das MAP Quinases , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/patologia , Pancitopenia/genética , Pancitopenia/patologia , Fator de Transcrição STAT5/fisiologia , Sequências de Repetição em Tandem , Tirosina Quinase 3 Semelhante a fms/genéticaAssuntos
Infecções por Campylobacter , Campylobacter jejuni , Gastroenterite , Pancitopenia , Infecções por Campylobacter/complicações , Infecções por Campylobacter/diagnóstico , Infecções por Campylobacter/fisiopatologia , Gastroenterite/complicações , Gastroenterite/diagnóstico , Gastroenterite/fisiopatologia , Humanos , Lactente , Masculino , Pancitopenia/etiologia , Pancitopenia/fisiopatologiaAssuntos
Pancitopenia/etiologia , Deficiência de Vitamina B 12/complicações , Deficiência de Vitamina B 12/tratamento farmacológico , Vitamina B 12/uso terapêutico , Pré-Escolar , Feminino , Seguimentos , Humanos , Pancitopenia/tratamento farmacológico , Pancitopenia/fisiopatologia , Medição de Risco , Resultado do Tratamento , Deficiência de Vitamina B 12/diagnósticoRESUMO
Non-cirrhotic portal hypertension (NCPH) encompasses a wide range of disorders, primarily vascular in origin, presenting with portal hypertension (PHT), but with preserved liver synthetic functions and near normal hepatic venous pressure gradient (HVPG). Non-cirrhotic portal fibrosis/Idiopathic PHT (NCPF/IPH) and extrahepatic portal venous obstruction (EHPVO) are two prototype disorders in the category. Etiopathogenesis in both of them centers on infections and prothrombotic states. Presentation and management strategies focus on repeated well tolerated episodes of variceal bleed and moderate to massive splenomegaly and other features of PHT. While the long-term prognosis is generally good in NCPF, portal biliopathy and parenchymal extinction after prolonged PHT makes outcome somewhat less favorable in EHPVO. While hepatic schistosomiasis, congenital hepatic fibrosis and nodular regenerative hyperplasia have their distinctive features, they often present with NCPH.
Assuntos
Hipertensão Portal/etiologia , Hemodinâmica , Humanos , Hipertensão Portal/fisiopatologia , Hipertensão Portal/terapia , Infecções/complicações , Fígado/patologia , Cirrose Hepática/etiologia , Cirrose Hepática/fisiopatologia , Pancitopenia/etiologia , Pancitopenia/fisiopatologia , Pressão na Veia Porta , Prognóstico , Esplenomegalia/etiologia , Esplenomegalia/fisiopatologia , Trombose Venosa/etiologia , Hipertensão Portal não Cirrótica IdiopáticaRESUMO
The objective of this study was to identify the different causes of death in calves affected with bovine neonatal pancytopenia (BNP). A total of 51 precolostral calves were fed with colostrum from cows which had lost at least one calf after parturition due to BNP in previous lactations. Clinical BNP could be induced in 71% (36/51) and subclinical BNP in 20% (10/51) of the calves. 9% (5/51) of the calves stayed BNP-unaffected despite challenging with the same mixed colostrum and approved passive transfer of colostral antibodies. The case fatality rate in BNP-affected cases was 83% (38/46). In the 38 lethal BNP-cases gross-pathological and histopathological examinations were performed. BNP-induced haemorrhagic anaemia was the cause of death in 18 calves (47%). 19 of these lethal cases (50%) died due to infectious diseases, especially due to pneumonia, enteritis and septicaemia. One calf died due to severe enteritis and exsiccosis without any signs of BNP (3%). In conclusion, anaemia as the consequence of haemorrhages was the most prevalent cause of death in BNP-affected calves, however, BNP has been approved to increase the lethality of common infectious neonatal diseases.
Assuntos
Doenças dos Bovinos , Pancitopenia , Anemia , Animais , Animais Recém-Nascidos , Bovinos , Doenças dos Bovinos/sangue , Doenças dos Bovinos/patologia , Doenças dos Bovinos/fisiopatologia , Colostro , Enterite , Feminino , Masculino , Pancitopenia/sangue , Pancitopenia/patologia , Pancitopenia/fisiopatologia , TrombocitopeniaRESUMO
Lymphohistiocytic activation syndrome (LHAS) is related to inappropriate stimulation of macrophage cells in bone marrow and lymphoid system. LHAS combines the non-specific clinical signs (fever, poor general condition, hepatosplenomegaly, lymphadenopathy) and suggestive biological elements (bi-or pancytopenia, abnormal liver function, coagulopathy, increased LDH, ferritin and triglycerides). The diagnosis of SALH remains an emergency every clinician should discuss before any febrile cytopenia. The etiology of LHAS is still obscure, but recent advances in the genetic study of familial forms provide some essential elements in understanding.
Assuntos
Pancitopenia/terapia , Síndrome , Diagnóstico Diferencial , Progressão da Doença , Humanos , Exame Neurológico , Pancitopenia/diagnóstico , Pancitopenia/epidemiologia , Pancitopenia/fisiopatologia , PrognósticoRESUMO
UNLABELLED: Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long-tem outcome of IPH by retrospectively studying 69 biopsy-proven cases of IPH. Mean duration of follow-up was 6.7 ± 4.6 years. All patients had evidence of portal hypertension (PH) at diagnosis, and 42% were symptomatic. Variceal bleeding (VB) was the most common manifestation. In those without bleeding at diagnosis, 74% had varices at first endoscopy. In those with large varices, the 1-year probability of first bleeding despite primary prophylaxis was 9%. The 1-year probability of rebleeding was 22%. Ascites and hepatic encephalopathy was documented in 26% and 7% of patients, respectively, at least once during the clinical course. The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients receiving anticoagulation achieved recanalization. Human immunodeficiency virus (HIV) infection and VB at diagnosis were the independent predictors of PVT. Seven patients died (6 as a result of an IPH-related cause) and 2 were transplanted. Probability of liver transplantation-free survival was 82% at 10 years. Presence of a severe associated disorder and ascites as a presenting symptom were associated with poor survival. CONCLUSION: Variceal bleeding is a major complication of IPH. Using, in IPH patients, the same management approach for PH as in cirrhosis is safe and maintains a low incidence of first bleeding and rebleeding in IPH patients. PVT is a frequent complication, particularly in those with HIV infection. Despite several complications, overall survival of patients with IPH is considerably good.